miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2

Yin,Yan; Liu,Hua; Xu,Junhui; Shi,Dongsheng; Zhai,Liang; Liu,Bin; Wang,Lei; Liu,Guangxin; Qin,Jianwen

doi:10.3892/or.2018.6772

miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2

Authors:
- Yan Yin
- Hua Liu
- Junhui Xu
- Dongsheng Shi
- Liang Zhai
- Bin Liu
- Lei Wang
- Guangxin Liu
- Jianwen Qin
View Affiliations

Affiliations: Respiratory and Critical Care Medicine of Tianjin Chest Hospital, Tianjin 300222, P.R. China, Department of Hepatology and Gastroenterology Tianjin Third Central Hospital of Tianjin, Tianjin 300170, P.R. China
Published online on: October 8, 2018 https://doi.org/10.3892/or.2018.6772
Pages: 3479-3488

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapeutic drug resistance is correlated with treatment failure and poor prognosis among lung cancer patients. Numerous studies indicate the relevance of miRNAs in inducing certain drug resistance. In the course of the study, we unexpectedly found that miR‑144‑3p could regulate the cisplatin resistance of lung cancer cells via Nrf2. However, Nrf2 also could reverse activate the expression of miR‑144‑3p by binding to the ARE box in the miR‑144‑3p promoter. This may be a self‑protection mechanism of the body. In addition, we also found that in other cancer cell lines, such as HepG2, miR‑144‑3p also had the function of regulating cisplatin resistance. These findings may provide some theoretical reference for the clinical inhibition of cisplatin resistance.

View Figures

View References

1	Jones GS and Baldwin DR: Recent advances in the management of lung cancer. Clin Med (Lond). 18 Suppl 2:S41–S46. 2018. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
4	Waqar SN and Morgensztern D: Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 180:16–23. 2017. View Article : Google Scholar : PubMed/NCBI
5	Tsvetkova E and Goss GD: Drug resistance and its significance for treatment decisions in non-small cell lung cancer. Curr Oncol. 19 Suppl 1:S45–S51. 2012.PubMed/NCBI
6	Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ and O'Byrne KJ: Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One. 8:e541932013. View Article : Google Scholar : PubMed/NCBI
7	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
8	Rudolph C, Melau C, Nielsen JE, Jensen Vile K, Liu D, Pena-Diaz J, Rajpert-De Meyts E, Rasmussen LJ and Jørgensen A: Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours. Cell Oncol (Dordr). 40:341–355. 2017. View Article : Google Scholar : PubMed/NCBI
9	Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, Tan PH, Ho GH and Lee AS: Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. 19:4477–4487. 2013. View Article : Google Scholar : PubMed/NCBI
10	Natalie G, Walker RC, Hee KC, Winter S and Hunter KW: Inherited variation in miR-290 expression suppresses breast cancer progression by targeting the metastasis susceptibility gene Arid4b. Cancer Res. 73:2671–2681. 2013. View Article : Google Scholar : PubMed/NCBI
11	Guarnieri DJ and Dileone RJ: MicroRNAs: A new class of gene regulators. Ann Med. 40:197–208. 2008. View Article : Google Scholar : PubMed/NCBI
12	Wahid F, Shehzad AT, Khan T and Kim YY: MicroRNAs: Synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 1803:1231–1243. 2010. View Article : Google Scholar : PubMed/NCBI
13	Hoelscher SC, Doppler SA, Dreßen M, Lahm H, Lange R and Krane M: MicroRNAs: Pleiotropic players in congenital heart disease and regeneration. J Thorac Dis. 9 Suppl 1:S64–S81. 2017. View Article : Google Scholar : PubMed/NCBI
14	Kastl L, Brown I and Schofield AC: miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat. 131:445–454. 2012. View Article : Google Scholar : PubMed/NCBI
15	Dongoran RA and Wu TY: Abstract 5269: Cryptotanshinone activate Nrf2 expression through microRNA regulations. Cancer Res. 77 Suppl 13:52692017. View Article : Google Scholar
16	Singh B, Ronghe AM, Chatterjee A, Bhat NK and Bhat HK: MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. Carcinogenesis. 34:1165–1172. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zhao L, Qi Y, Xu L, Tao X, Han X, Yin L and Peng J: MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. Redox Biol. 15:284–296. 2018. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
20	Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
21	Periti P and Mini E: Drug resistance in cancer: An overview of the clinical aspects. J Chemother. 1:5–9. 1989. View Article : Google Scholar : PubMed/NCBI
22	Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y, Wang Y, Chen Q, Zhao X, Zhou M, et al: MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat. 139:717–730. 2013. View Article : Google Scholar : PubMed/NCBI
23	Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai XF, Yu ZJ, Wu HZ, Sun ML, Song ZG and Wei MJ: miR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett. 339:107–115. 2013. View Article : Google Scholar : PubMed/NCBI
24	Schwabedissen Meyer zu HE and Kroemer HK: In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 1–371. 2011.
25	Zhang Q, Zhang B, Sun L, Yan Q, Zhang Y, Zhang Z, Su Y and Wang C: MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/β-catenin pathway. Cell Biochem Funct. 36:194–202. 2018. View Article : Google Scholar : PubMed/NCBI
26	Niture SK and Jaiswal AK: Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance. Free Radic Biol Med. 57:119–131. 2013. View Article : Google Scholar : PubMed/NCBI
27	Niture SK and Jaiswal AK: Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem. 287:9873–9886. 2012. View Article : Google Scholar : PubMed/NCBI
28	Young LC, Campling BG, Cole SP, Deeley RG and Gerlach JH: Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 7:1798–1804. 2001.PubMed/NCBI
29	Hayes JD, McMahon M, Chowdhry S and Dinkova-Kostova AT: Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal. 13:1713–1748. 2010. View Article : Google Scholar : PubMed/NCBI
30	Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, et al: Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 16:3743–3753. 2010. View Article : Google Scholar : PubMed/NCBI
31	Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N, et al: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI